Title: Absence of the beta 1 subunit of AMP-activated protein kinase reduces myofibroblast infiltration of the kidneys in early diabetes
Authors: Choy, SW
Fraser, SA
Katerelos, M
Galic, S
Kemp, BE
Mount, PF
Power, DA
Issue Year: 2019
Publisher WILEY
Abstract AimsWe investigated which serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels inform heart failure (HF) risk in a community-based population at increased cardiovascular disease (CVD) risk. Methods and resultsInclusion criteria were age 60years with one or more of self-reported hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment. Exclusion criteria were known HF, ejection fraction (EF) <50%, ormore thanmild valve abnormality. NT-proBNP levels were measured in 3842 participants on enrolment. HF was diagnosed in 162 participants at a median of 4.5 (interquartile range 2.7-5.4) years after enrolment, 73 with HF with preserved EF (HFpEF), 53 with HF with reduced EF (HFrEF), and 36 with valvular HF (VHF). Areas under the receiver operating characteristic curve (AUC) for 5-year prediction of total HF were similar for NT-proBNP alone (0.79, 95% confidence interval 0.74-0.83) and a 7-parameter multivariable model (0.82, 0.77-0.86, P=0.035). NT-proBNP cut-points of 11, 16, and 25pmol/L for individuals aged 60-69, 70-79, and 80years, respectively, achieved sensitivities >76% and specificities of 47-69% for 5-year prediction of total HF in men and women in all three age groups. Sensitivities were 75% in most subgroups according to body mass index, estimated glomerular filtration rate, and the presence or absence of atrial fibrillation, pacemaker, or CVD, and for the prediction of HFpEF, HFrEF and VHF. ConclusionAge-specific serum NT-proBNP levels inform prognosis, and hence therapeutic decisions, regarding HF risk in individuals at increased CVD risk.
URI: https://publications.svi.edu.au/publications/7879
Other Identifiers 10.1111/iep.12313
Publication type Article